In vitro solubility and in vivo toxicity of gallium arsenide.
The in vitro solubilities of gallium arsenide (GaAs) and its metal oxides were arsenic(III) oxide greater than GaAs much greater than gallium(III) oxide. GaAs dissolution was also dependent upon the type and concentration of buffer anion. The amount of arsenic dissolved in 12 hr by various aqueous media was 0.2 M phosphate buffer greater than or equal to 0.1 M phosphate buffer greater than Krebs-Hensleit buffer greater than distilled H2O greater than HCl-KCl buffer. GaAs was apparently soluble under in vivo conditions. Blood arsenic concentrations in rats 14 days after intratracheal instillation of 10, 30, or 100 mg/kg GaAs were 5.5, 14.3, and 53.6 micrograms/ml, respectively; gallium was not detected at any doses. An increase in lung wet weight at 14 days was dose dependent with these organs retaining 17 to 42% of the dose as gallium or arsenic. Excretion of gallium and arsenic was limited to the feces. Urinary porphyrin concentrations and body weight, monitored as indices of toxicity, were significantly altered over the 14-day study. The analysis of porphyrins revealed that uroporphyrin replaced coproporphyrin as the primary urinary metabolite. Rats receiving 10, 100, or 1000 mg/kg GaAs po exhibited similar signs of toxicity. Blood arsenic concentrations at 14 days were 3.5, 6.8, and 17.6 micrograms/ml, respectively. Porphyria was increased, and body weight was decreased at 1000 mg/kg GaAs. These values were equivalent to those obtained with an intratracheal dose of 10 to 30 mg/kg GaAs. Our results showed that pulmonary and po exposure to GaAs resulted in systemic arsenic intoxication. The finding that urinary uroporphyrin concentrations were greater than coproporphyrin concentrations may serve as a sensitive indicator for GaAs exposure.
D000818:Animals; D001151:Arsenic / Q000009:adverse effects* / Q000032:analysis* / Q000378:metabolism; D000077237:Arsenic Trioxide; D001152:Arsenicals; D001835:Body Weight / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005243:Feces / Q000032:analysis; D005708:Gallium / Q000009:adverse effects* / Q000032:analysis / Q000378:metabolism; D008168:Lung / Q000187:drug effects; D008297:Male; D009929:Organ Size / Q000187:drug effects; D010087:Oxides; D011166:Porphyrins / Q000652:urine; D051381:Rats; D011916:Rats, Inbred F344; D012995:Solubility
D001152:Arsenicals; D010087:Oxides; D011166:Porphyrins; C043055:gallium arsenide; C038863:gallium oxide; D005708:Gallium; D001151:Arsenic; D000077237:Arsenic Trioxide